Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2023

20-09-2022 | Hepatitis C | Original Research

Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014–2020

Authors: Marguerite E. Beiser, MS, Leah C. Shaw, MPH, Giavanna A. Wilson, BFA, Khadija O. Muse, MPA, Savanna K. Shores, BSN, Travis P. Baggett, MD, MPH

Published in: Journal of General Internal Medicine | Issue 4/2023

Login to get access

Abstract

Background

Engaging people experiencing homelessness or unstable housing in hepatitis C virus (HCV) treatment is critical to achieving HCV elimination.

Objective

To describe HCV treatment outcomes, including factors associated with retention through the treatment cascade, for a cohort of individuals treated in a homeless health center in Boston.

Design

Retrospective cohort study.

Participants

All individuals who initiated HCV treatment with Boston Health Care for the Homeless Program’s HCV treatment program between January 2014 and March 2020 (N = 867).

Outcome Measures

The primary outcome was sustained virologic response (SVR), defined as an HCV ribonucleic acid (RNA) level ≤ 15 IU/mL at least 12 weeks after treatment completion. We used multivariable logistic regression to examine the association between baseline variables and SVR. Process-oriented outcomes included treatment completion, assessment for SVR, and achievement of SVR.

Results

Of 867 individuals who started HCV treatment, 796 (91.8%) completed treatment, 678 (78.2%) were assessed for SVR, and 607 (70.0%) achieved SVR. In adjusted analysis, residing in stable housing (OR 3.83, 95% CI 1.85–7.90) and age > 45 years old (OR 1.53, 95% CI 1.04–2.26) were associated with a greater likelihood of achieving SVR. Recent drug use (OR 0.63, 95% CI 0.41–0.95) was associated with a lower likelihood of SVR. Age, housing status, and drug use status impacted retention at every step in the treatment cascade.

Conclusion

A large proportion of homeless-experienced individuals engaging in HCV treatment in a homeless health center achieved SVR, but enhanced approaches are needed to engage and retain younger individuals, those with recent or ongoing substance use, or those experiencing homelessness or unstable housing. Efforts to achieve HCV elimination in this population should consider the complex and overlapping challenges experienced by this population and aim to address the fundamental harm of homelessness itself.
Literature
2.
go back to reference Gelberg L, Robertson MJ, Arangua L, et al. Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep. 2012;127(4):407-21. Gelberg L, Robertson MJ, Arangua L, et al. Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep. 2012;127(4):407-21.
8.
go back to reference Hashim A, Macken L, Jones A, McGeer M, Aithal G, Verma S. Community-based assessment and treatment of hepatitis C virus-related liver disease, injecting drug and alcohol use amongst people who are homeless: a systematic review and meta-analysis. Int J Drug Policy. 2021;96:103342. https://doi.org/10.1016/j.drugpo.2021.103342. Hashim A, Macken L, Jones A, McGeer M, Aithal G, Verma S. Community-based assessment and treatment of hepatitis C virus-related liver disease, injecting drug and alcohol use amongst people who are homeless: a systematic review and meta-analysis. Int J Drug Policy. 2021;96:103342. https://​doi.​org/​10.​1016/​j.​drugpo.​2021.​103342.
15.
16.
go back to reference Harney BL, Whitton B, Lim C, et al. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int J Drug Policy. 2019. Harney BL, Whitton B, Lim C, et al. Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia. Int J Drug Policy. 2019.
20.
21.
go back to reference Litwin AH, Lum PJ, Taylor LE, et al. A multisite randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: the HERO Study - Hepatitis C Real Options 2020. Litwin AH, Lum PJ, Taylor LE, et al. A multisite randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: the HERO Study - Hepatitis C Real Options 2020.
24.
25.
go back to reference Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41-5. https://doi.org/10.1002/hep.27366. Yoshida EM, Sulkowski MS, Gane EJ, et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41-5. https://​doi.​org/​10.​1002/​hep.​27366.
26.
go back to reference Sulkowski M, Feld J, Reau N, et al. Concordance between SVR4, SVR12, and SVR24 in HCV-infected. Patients who received fixed-dose combination sofosbuvir/velpatasvir in phase 3 clinical trials. Poster presented at: International Liver Congress; June 23-26, 2021 2021; virtual. Accessed 6/29/22. Sulkowski M, Feld J, Reau N, et al. Concordance between SVR4, SVR12, and SVR24 in HCV-infected. Patients who received fixed-dose combination sofosbuvir/velpatasvir in phase 3 clinical trials. Poster presented at: International Liver Congress; June 23-26, 2021 2021; virtual. Accessed 6/29/22.
Metadata
Title
Factors Associated with Sustained Virologic Response to Hepatitis C Treatment in a Homeless-Experienced Cohort in Boston, 2014–2020
Authors
Marguerite E. Beiser, MS
Leah C. Shaw, MPH
Giavanna A. Wilson, BFA
Khadija O. Muse, MPA
Savanna K. Shores, BSN
Travis P. Baggett, MD, MPH
Publication date
20-09-2022
Publisher
Springer International Publishing
Keyword
Hepatitis C
Published in
Journal of General Internal Medicine / Issue 4/2023
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-022-07778-w

Other articles of this Issue 4/2023

Journal of General Internal Medicine 4/2023 Go to the issue

Healing Arts

The Space Between

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine